Noblia Advisors Resources
Emerging Markets Update
June 2017
Noblia Advisors' Emerging Markets Update. Published June 23, 2017
Global Business News
Noblia Advisors' recap of business news that matter from around the globe. Published June 23, 2017
Country Updates
Argentina
This January 2016 Noblia Advisors Country Update reviews key facts about the Argentine economy and new business opportunities under President Macri's administration. By Eduardo Campomar © Noblia Advisors.
News
Noblia Advisors announces the expansion of its practice in South America through a partnerhip with Mr. Eduardo Campomar, Managing Director, Rainmaker Consulting. January, 2016.
Recommended Reading
Classics: Peter Drucker on Making Decisions
In this 2004 excerpt from the Harvard Business Review you can read in five minutes this legendary management consultant’s reflections on what makes an executive effective.
This June 2017 World Bank report discusses the current environment of a fragile global economic recovery. © World Bank Group, 2017.
Latin America Trade Trend Estimates
This May 2017 report by the Inter-American Development Bank (BID) presents Latin American and Caribbean International Trade Trend Estimates. © Inter-American Development Bank.
Income Polarization in the United States
This March 2017 IMF Research Bulletin discusses the implications of a shrinking middle-class and its effect on consumption. By Ali Alichi, Kory Kantenga, and Juan Solé. © International Monetary Fund.
In the news
CNN
Goldman Sachs slants research to help Democrats, top White House adviser says
Kevin Hassett, President Donald Trump's top economic adviser, suggested Goldman Sachs may be slanting its economic research to help Democrats ahead of the midterm elections.
Land O'Lakes CEO Beth Ford, from the cornfield to the C-suite
Land O'Lakes CEO Beth Ford charts her career path, from her first job to becoming the first openly gay CEO at a Fortune 500 company in an interview with CNN's Boss Files.
The next big test for Elon Musk arrives this week
Read full story for latest details.
The next big test for Elon Musk arrives this week
Read full story for latest details.
WSJ
Stocks Sink in Broad AI Rout Sparked by China's DeepSeek
U.S. stocks were mostly lower, with the Nasdaq leading declines as makers of AI infrastructure suffered steep falls, many in the double digits. Nvidia was down 16%.
Comex Gold, Silver Settle Lower
Gold settled 1.4% lower, down two of the past three sessions, and silver fell 2.5%, down three of the past four sessions.
DeepSeek Won't Sink U.S. AI Titans
Panic fueling the selloff of Nvidia, Broadcom and other tech giants is overblown.
Financial Services Roundup: Market Talk
Gain insight on Experian, SoFi Technologies and more in the latest Market Talks covering Financial Services.
BBC
Watch: Moment 64-year-old Nepali woman is found alive in mud-buried home
Chandika Shrestha was airlifted to hospital after spending more than 10 days in her partially buried house.
US envoys meet Putin in Moscow for Ukraine talks
Footage shows Vladimir Putin greeting Steve Witkoff and Jared Kushner, before saying the current situation "is not so easy".
'He was a lifeline' - Families at a loss after Haitian caregivers let go in US
Haitian immigrants make up a large portion of the already overburdened home-care workforce.
Majority Russian-speaking city in Ukraine considers language ban in the arts
Ukraine's third-biggest city Odesa decides this week whether to ban Russian-language content in music and literature in public.
NYT News
Kenyans Made a Living Writing College Essays. Then A.I. Arrived.
Thousands of Kenyans made a living writing essays for overseas students. With A.I., the work has dried up, a warning for online gig work that has been a global lifeline.
E. Coli Illnesses Linked to Frozen Blueberries Are Up to 17, F.D.A. Says
The affected frozen fruit products, which were distributed to 19 states and to retailers like Walmart and Publix, were recalled starting in July.
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.